Dosage evidence
PT-141 (bremelanotide) Dosage: What the FDA Label Actually Says
Approved as VYLEESI for hypoactive sexual desire disorder in premenopausal women, with an explicit ceiling on how often it may be used.
Where PT-141 (bremelanotide) stands with the FDA
The labeled doses
| Dose | Route | Frequency | Approved for |
|---|---|---|---|
1.75 mg Current FDA label | Subcutaneous injection in the abdomen or thigh | At least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours, and more than 8 doses per month is not recommended | Premenopausal women with acquired, generalized hypoactive sexual desire disorder |
Read the “Approved for” column before anything else. A labeled dose belongs to the population it was studied in. It is not a general-purpose number, and it is not automatically the right dose for a different indication.
Convert your prescribed dose to syringe units
If a clinician has prescribed PT-141 (bremelanotide) for you, the number that matters next is how far to draw the syringe — and that depends on how much bacteriostatic water went into the vial, not on the peptide itself. Note the unit change: the doses above are written in milligrams, and the calculator takes micrograms. Multiply by 1,000 — a 1.4 mg dose is 1,400 mcg.
This converts a dose your prescriber has already given you into a volume and a number of units on a U-100 insulin syringe. It does not suggest a dose, and it does not tell you whether a peptide is appropriate for you. Most research peptides have no FDA-approved dosing, so there is no “standard” number for us to fill in. Doses here are in micrograms (mcg) — confusing mcg with mg is a 1,000-fold error and the single most common way people get this wrong.
Enter the dose your prescriber gave you, in micrograms, to see the volume and syringe units.
Your 5 mg vial in 2 mL of bacteriostatic water is —.
Keep reading
References
- 1.Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide injection) — US Prescribing Information, Dosage and Administration. FDA DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
This page reports what regulators and published sources say about PT-141 (bremelanotide). It is not medical advice, not a recommendation to use PT-141 (bremelanotide), and not a dosing instruction. Every source above was opened and read on the date recorded in our data; regulatory status changes, so check the primary source before relying on it.